Business Wire

Murata’s Revolutionary Stretchable Printed Circuit Elevates Wearable Medical Devices

Share

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) reveals an innovative new Stretchable Printed Circuit (SPC) technology marking a significant development in printed circuit technology. Murata's SPC represents the next advancement in substrate development, providing both flexibility and the capability to stretch and deform while maintaining full functionality. It is perfect for creating advanced medical products, like wearable therapeutic devices and vital monitoring tools, that can provide better accuracy, durability, and patient comfort than today’s equivalent devices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241029672185/en/

[Murata Manufacturing Co., Ltd.] Murata’s Stretchable Printed Circuit (SPC) (Photo: Business Wire)

In recent years, in the medical field, to make more accurate diagnoses, the importance of sophisticated tests performed in hospitals and biometric information collected continuously in daily life has increased. Daily vital sign monitoring is important to prevent lifestyle-related diseases, therefore wearable medical devices are now ubiquitous. However, existing devices are often too stiff for many applications, creating issues like patient discomfort, poor surface contact, or unstable data acquisition. Murata's SPC excels in its inherent flexibility, stretchability, and ability to adapt, supporting multi-sensing functionalities to address diverse user requirements. The material is incredibly soft and gentle on the skin, making it ideal for medical and wellness devices like EEG (Electroencephalogram), EMG (Electromyogram), and ECG (Electrocardiogram). Its stretchable nature can enable a single device to accommodate various body areas and patients of different sizes, as well as allowing more easily for continuous monitoring applications or monitoring in previously challenging areas such as elbows or knee joints.

Engineered with cutting-edge capabilities, including printing stretchable electrodes compliant with ANSI/AAMI EC12 standards, SPC paves the way for next-generation medical devices. It achieves seamless integration and optimal performance through innovative telescopic component mounting and hybrid bonding technology between substrates. By effectively blocking electromagnetic noise, the unique shield layer offers reliable protection for the signal path. Additionally, the substrate construction demonstrates excellent reliability, with high resistance to moisture and the ability to withstand high voltages for long durations, while allowing for more flexibility in component mounting, giving designers more freedom to innovate.

Murata's SPC can be tailored to meet individual customer specifications with the help of Murata’s extensive range of resources to facilitate collaborative product development. This can be harnessed by product designers, enabling them to optimize their designs. Murata can further support development by conducting tests in various conditions and resolving failure modes by identifying their root causes. Depending on the required specifications, filters, amplifiers, and multiple sensors can be mounted on a single sheet, enabling accurate data acquisition and sensing of several items. With this solution, Murata performs custom design, prototyping and verification, and mass production based on the required specifications.

For further details or to request samples of Murata’s SPC solutions, you can contact your local Murata representation, or reach out via the contact form. You can find the product webpage here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241029672185/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 22:51:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 20:30:00 CEST | Press release

Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapyPatients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Thi

DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu15.5.2025 20:23:00 CEST | Press release

DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational HighlightsRevenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit marg

Ras Al Khaimah’s Strong Economic and Investment Environment Validated by Fitch Affirmation of ‘A+’ Credit Rating, With Stable Outlook15.5.2025 20:18:00 CEST | Press release

The positive rating reflects the Emirate’s strong long-term growth prospects and ongoing economic diversification Ras Al Khaimah’s strategic approach to sustainable, cross-sector growth and strong economic and investment environment has been validated by international credit rating agency Fitch, which reaffirmed the rating at ‘A+’ with a stable outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515907689/en/ Ras Al Khaimah’s strong economic and investment environment validated by Fitch affirmation of ‘A+’ credit rating, with Stable Outlook (Photo: AETOSWire) Ras Al Khaimah Government welcomed the announcement as an endorsement of the Emirate’s resilient and expanding economy, sound fiscal management and the clear vision and unwavering commitment of its leadership to sustainable, long-term development and growth. The Emirate’s landmark tourism projects, including a major integrated resort, luxury hotels and world-clas

Cessna Citation CJ4 Gen3 Flight Test Program Advances Through Milestones as Second Test Article Takes Flight15.5.2025 20:00:00 CEST | Press release

Textron Aviation today announced a major program milestone for the Cessna Citation CJ4 Gen3 flight test program with the successful first flight of a second test article — P1. Testing on the P1 aircraft will focus on avionics, human factors and interiors. The Citation CJ4 Gen3 business jet is designed to keep pilots a step ahead in the cockpit by offering the next-generation Garmin G3000 PRIME avionics along with the most standard features in its class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515438856/en/ Cessna Citation CJ4 Gen3 flight test program advances through milestones as second test article takes flight. (Photo Credit: Textron Aviation) The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “This achievement continues the forward momentum of the CJ4 Gen3 program and reflects the dedication and expertise of our team in designing, certifying an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye